Brokerages Set Avantor, Inc. (NYSE:AVTR) Target Price at $27.57

Shares of Avantor, Inc. (NYSE:AVTR) have been assigned a consensus rating of “Moderate Buy” from the fifteen ratings firms that are currently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and twelve have given a buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $27.57.

Several research firms have issued reports on AVTR. Morgan Stanley increased their price objective on Avantor from $28.00 to $29.00 and gave the stock an “overweight” rating in a research note on Monday, July 29th. TD Cowen increased their price objective on Avantor from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Monday, July 29th. Stifel Nicolaus increased their price objective on Avantor from $27.00 to $28.00 and gave the stock a “buy” rating in a research note on Monday, July 29th. Robert W. Baird dropped their price objective on Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research note on Monday, October 28th. Finally, Barclays dropped their price objective on Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a research note on Friday, October 25th.

Insider Activity at Avantor

In other Avantor news, CAO Steven W. Eck sold 3,525 shares of the business’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $25.06, for a total transaction of $88,336.50. Following the completion of the sale, the chief accounting officer now directly owns 29,544 shares of the company’s stock, valued at approximately $740,372.64. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.30% of the stock is currently owned by company insiders.

Institutional Trading of Avantor

Several institutional investors and hedge funds have recently added to or reduced their stakes in AVTR. Intech Investment Management LLC grew its position in shares of Avantor by 1.8% during the 2nd quarter. Intech Investment Management LLC now owns 29,068 shares of the company’s stock worth $616,000 after buying an additional 514 shares during the period. Arizona State Retirement System grew its position in shares of Avantor by 0.3% in the 2nd quarter. Arizona State Retirement System now owns 186,567 shares of the company’s stock valued at $3,955,000 after purchasing an additional 528 shares during the period. Veracity Capital LLC grew its position in shares of Avantor by 1.0% in the 3rd quarter. Veracity Capital LLC now owns 52,359 shares of the company’s stock valued at $1,355,000 after purchasing an additional 543 shares during the period. Wealth Enhancement Advisory Services LLC grew its position in shares of Avantor by 2.8% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 26,921 shares of the company’s stock valued at $571,000 after purchasing an additional 733 shares during the period. Finally, US Bancorp DE grew its position in shares of Avantor by 6.2% in the 3rd quarter. US Bancorp DE now owns 12,615 shares of the company’s stock valued at $326,000 after purchasing an additional 734 shares during the period. 95.08% of the stock is owned by institutional investors.

Avantor Stock Down 1.7 %

Shares of AVTR stock opened at $22.59 on Wednesday. The stock has a market cap of $15.37 billion, a P/E ratio of 49.11, a price-to-earnings-growth ratio of 2.73 and a beta of 1.35. Avantor has a one year low of $18.08 and a one year high of $28.00. The stock has a fifty day moving average price of $24.91 and a 200 day moving average price of $24.12. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.54 and a quick ratio of 1.06.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.